Clinical Trials Currently Recruiting Participants

For more information please visit

Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-interventional Study (POLARIS)

  • Sponsor:  Pfizer
  • Identifier:  NCT03280303

A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (BROCADE 3)

  • Sponsor:  AbbVie
  • Identifier:  NCT02163694

A phase II, multicenter, open-label, two-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in patients with HR+, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor whose disease has progressed on or after CDK 4/6 inhibitor containing treatments (ByLieve)

  • Sponsor:  Novartis Pharmaceuticals
  • Identifier:  NCT03056755

Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with ER-positive, HER2-negative Early Breast Cancer (FELINE)

  • Sponsor:  Qamar Khan, University of Kansas Medical Center
  • Collaborator:  Novartis Pharmaceuticals
  • Clinical Identifier:  NCT02712712

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib for Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer

  • Sponsor:  Pfizer
  • Identifier:  NCT03499353

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T DM1

  • Sponsor:  Daiichi Sankyo, Inc.
  • Identifier:  NCT03523585

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

  • Sponsor:  Daiichi Sankyo, Inc.
  • Identifier:  NCT03529110

Clinical Studies that are On-going, not Recruiting Participants

For more information please visit

An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer (BOLERO 4)

  • Sponsor:  Novartis Pharmaceuticals
  • Identifier:  NCT01698918

A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation with Cancer Clinical Outcomes

  • Sponsor:  Caris Science, Inc.
  • Identifier:  NCT02678754

A Study of Atezolizumab in Combination with Nab-Paclitaxel Compared With Placebo with Nab-Paclitaxel for Participants with Previously Untreated Metastatic Triple-Negative Breast Cancer (IMPASSION)

  • Sponsor:  Hoffman-LaRoche
  • Identifier:  NCT02425891

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

  • Sponsor:  Hoffman-LaRoche
  • Identifier:  NCT02924883

Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System

  • Sponsor:  Xoft, Inc.
  • Collaborator:  Icad, Inc.
  • Identifier:  NCT01644669

Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (ICE3)

  • Sponsor:  IceCure Medical Ltd.
  • Identifier:  NCT02200705

Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST)

  • Sponsor:  Agendia
  • Identifier:  NCT01479101

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery (B-40)

  • Sponsor:  NSABP Foundation, Inc.
  • Collaborator:  National Cancer Institute
  • Identifier:  NCT00408408

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer (B-42)

  • Sponsor:  NSABP Foundation, Inc.
  • Collaborator:  National Cancer Institute
  • Identifier:  NCT00382070

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (B-43)

  • Sponsor:  NSABP Foundation, Inc.
  • Collaborator:  National Cancer Institute
  • Identifier:  NCT00769379

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (PUMA 3004)

  • Sponsor:  Puma Biotechnology, Inc.
  • Identifier:  NCT00878709

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. (SWOG SO307)

  • Sponsor:  Southwest Oncology Group
  • Collaborators: 
    • National Cancer Institute
    • North Central Cancer Treatment Group
    • Eastern NSABP Foundation
    • Cancer & Leukemia Group
    • NCIC Clinical Trials Group
  • Identifier:  NCT00127205

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

  • Sponsor:  Hoffman-LaRoche
  • Collaborators:
    • NSABP Foundation
    • German Breast Group
  • Identifier:  NCT0177247